GlassScriptPhysician profile
Abdul Malik Sheikh
NPI 1518925981
$56,532.58
in general payments reported to CMS, 2019-2025
30 companies · $4,060 in 2025
The $4,060 reported for 2025 was more than what 80% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $22K · 2021: $855 · 2022: $712 · 2023: $900 · 2024: $579 · 2025: $4,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Food and Beverage: $2,069 · Travel and Lodging: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Food and Beverage | $2,068.74 |
| Travel and Lodging | $971.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $52,351.77 | 2019-2025 | Vitalyst, Avvigo Guidance System, Ilab Ultrasound Imaging System |
| Medtronic Vascular, INC. | $861.21 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $387.83 | 2019-2025 | |
| Abiomed | $333.80 | 2019-2023 | Impella |
| W. L. Gore & Associates, INC. | $312.72 | 2019-2021 | |
| Abbott Laboratories | $307.93 | 2021-2024 | Cardiomems |
| Teleflex LLC | $306.04 | 2022-2023 | Guideliner, Turnpike |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $206.35 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $154.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $143.73 | 2021-2024 | Verquvo |
| Shockwave Medical, INC | $141.48 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $136.24 | 2020-2025 | Repatha, Repatha |
| Medtronic, INC. | $125.32 | 2021-2024 | Onyx Frontier, Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $116.98 | 2023-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $115.34 | 2021-2025 | Wainua |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $103.58 | 2019-2025 | |
| Novo Nordisk INC | $102.71 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Cvrx, INC. | $63.95 | 2023 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.05 | 2021-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $26.29 | 2022 | |
| Edwards Lifesciences Corporation | $24.78 | 2025 | Pascal |
| Bayer Healthcare Pharmaceuticals INC. | $21.68 | 2025 | |
| Philips North America LLC | $20.53 | 2021 | |
| Inari Medical, INC. | $19.92 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $17.84 | 2023 | Inpefa |
| Irhythm Technologies, INC. | $16.50 | 2019 | |
| Cordis US Corp. | $16.24 | 2024 | Mynx Control |
| Esperion Therapeutics, INC. | $14.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.42 | 2022 | |
| Kestra Medical Technology Services, INC. | $11.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.